Identification of neurodegeneration-monitoring biomarkers would be of great clinical value for Alzheimer’s disease (AD) diagnosis. Using N- or C-terminal antibodies, we studied the pro-survival synaptic effector, Kidins220, in the brain and cerebrospinal fluid (CSF) of controls and AD patients. Only the N-terminal antibody showed a positive correlation between Kidins220 and phosphorylated tau in AD brains. Using this antibody, Kidins220 was detected in CSF from AD patients where it positively correlated with CSF phosphorylated tau and tau. This study highlights the potential of Kidins220 as a CSF biomarker in AD.
QuerfurthHW, LaFerlaFM (2010) Alzheimer’s disease. N Engl J Med362, 329–344.
2.
ŠimićG, Babić LekoM, WrayS, HarringtonC, DelalleI, Jovanov-MiloševićN, BažadonaD, BuéeL, de SilvaR, Di GiovanniG, WischikC, HofPR (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules6, 6.
3.
MulderC, VerweyNA, van der FlierWM, BouwmanFH, KokA, van ElkEJ, ScheltensP, BlankensteinMA (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem56, 248–253.
4.
BlennowK, ZetterbergH (2015) The past and the future of Alzheimer’s disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci9, 345.
5.
IglesiasT, Cabrera-PochN, MitchellMP, NavenTJ, RozengurtE, SchiavoG (2000) Identification and cloning of Kidins220, a novel neuronal substrate of protein kinase D. J Biol Chem275, 40048–40056.
6.
KongH, BoulterJ, WeberJL, LaiC, ChaoMV (2001) An evolutionarily conserved transmembrane protein that is a novel downstream target of neurotrophin and ephrin receptors. J Neurosci21, 176–185.
7.
Lopez-MenendezC, GasconS, SobradoM, VidaurreOG, HigueroAM, Rodriguez-PenaA, IglesiasT, Diaz-GuerraM (2009) Kidins220/ARMS downregulation by excitotoxic activation of NMDARs reveals its involvement in neuronal survival and death pathways. J Cell Sci122, 3554–3565.
8.
NeubrandVE, CescaF, BenfenatiF, SchiavoG (2012) Kidins220/ARMS as a functional mediator of multiple receptor signalling pathways. J Cell Sci125, 1845–1854.
9.
DawbarnD, AllenSJ (2003) Neurotrophins and neurodegeneration. Neuropathol Appl Neurobiol29, 211–230.
10.
Lopez-MenendezC, Gamir-MorrallaA, Jurado-ArjonaJ, HigueroAM, CampaneroMR, FerrerI, HernandezF, AvilaJ, Diaz-GuerraM, IglesiasT (2013) Kidins220 accumulates with tau in human Alzheimer’s disease and related models: Modulation of its calpain-processing by GSK3beta/PP1 imbalance. Hum Mol Genet22, 466–482.
11.
CescaF, YabeA, Spencer-DeneB, ArrigoniA, Al-QatariM, HendersonD, PhillipsH, KoltzenburgM, BenfenatiF, SchiavoG (2011) Kidins220/ARMS is an essential modulator of cardiovascular and nervous system development. Cell Death Dis2, e226.
12.
Cabrera-PochN, Sanchez-RuilobaL, Rodriguez-MartinezM, IglesiasT (2004) Lipid raft disruption triggers protein kinase C and Src-dependent protein kinase D activation and Kidins220 phosphorylation in neuronal cells. J Biol Chem279, 28592–28602.
13.
SalaI, Belen Sanchez-SaudinosM, Molina-PorcelL, LazaroE, GichI, ClarimonJ, Blanco-VacaF, BlesaR, Gomez-IslaT, LleoA (2008) Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord26, 506–512.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
16.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
17.
TeunissenCE, TumaniH, BennettJL, BervenFS, BrundinL, ComabellaM, FranciottaD, FederiksenJL, FlemingJO, FurlanR, HintzenRQ, HughesSG, JimenezCR, JohnsonMH, KillesteinJ, KrasulovaE, KuhleJ, MagnoneMC, PetzoldA, RajdaC, RejdakK, SchmidtHK, van PeschV, WaubantE, WolfC, DeisenhammerF, GiovannoniG, HemmerB (2011) Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int2011, 246412.
18.
Gamir-MorrallaA, Lopez-MenendezC, Ayuso-DoladoS, TejedaGS, MontanerJ, RosellA, IglesiasT, Diaz-GuerraM (2015) Development of a neuroprotective peptide that preserves survival pathways by preventing Kidins220/ARMS calpain processing induced by excitotoxicity. Cell Death Dis6, e1939.
19.
SorimachiY, HaradaK, YoshidaK (1996) Involvement of calpain in postmortem proteolysis in the rat brain. Forensic Sci Int81, 165–174.
20.
StreetJM, BarranPE, MackayCL, WeidtS, BalmforthC, WalshTS, ChalmersRT, WebbDJ, DearJW (2012) Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med10, 5.
21.
Lopez-FontI, Cuchillo-IbanezI, Sogorb-EsteveA, Garcia-AyllonMS, Saez-ValeroJ (2015) Transmembrane amyloid-related proteins in CSF as potential biomarkers for Alzheimer’s disease. Front Neurol6, 125.
22.
SamanS, KimW, RayaM, VisnickY, MiroS, JacksonB, McKeeAC, AlvarezVE, LeeNC, HallGF (2012) Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem287, 3842–3849.
